A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Latest Information Update: 21 Jul 2023
At a glance
- Drugs Fusidic acid (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms REPRIEVE Study
- Sponsors Aceragen
Most Recent Events
- 17 Jul 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Feb 2023 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
- 14 Feb 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.